Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 5 publications
Avapritinib achieves long-term disease control with favorable safety in patients with indolent systemic mastocytosis over 3 years.
Journal: The Journal of allergy and clinical immunology
Published: December 16, 2025
Apitegromab for lean mass preservation during tirzepatide-induced weight loss: a randomized, double-blind, placebo-controlled phase 2 trial.
Journal: Nature medicine
Published: December 12, 2025
Avapritinib improves cutaneous involvement in patients with indolent systemic mastocytosis: Results from the randomized, phase 2, interventional PIONEER study.
Journal: Journal of the American Academy of Dermatology
Published: March 24, 2025
Phase III Trial of Avelumab Maintenance After First-Line Induction Chemotherapy Versus Continuation of Chemotherapy in Patients With Gastric Cancers: Results From JAVELIN Gastric 100.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: November 16, 2020
Avelumab (anti-PD-L1) as first-line switch-maintenance or second-line therapy in patients with advanced gastric or gastroesophageal junction cancer: phase 1b results from the JAVELIN Solid Tumor trial.
Journal: Journal for immunotherapy of cancer
Published: October 24, 2018
Showing 1-5 of 5
Last Updated: 09/26/2026